Learn More
Medchemexpress LLC BDP9066 | 2226507-04-4 | 98.2% | 348.44 | 10 MG

Supplier: Medchemexpress LLC HY11142410MG
BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor. It has an IC50 of 64 nM for MRCKβ in SCC12 cells, and Ki values of 0.0136 nM and 0.0233 nM for MRCKα/β respectively. It demonstrates a therapeutic effect on skin cancer by reducing substrate phosphorylation. This product is for research use only.
- Targets MRCKα (0.0136 nM (Ki)) and MRCKβ (0.0233 nM (Ki))
- Shows antiproliferative effects with greatest activity in hematologic cancer cells
- Inhibits MLC phosphorylation and blocks SCC12 squamous cell carcinoma motility and invasion
- Topical application significantly decreases phosphorylated MRCKα S1003 staining and tumor volumes
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.